Nefazodone can cause severe [[hepatotoxicity|liver damage]] leading to a need for liver transplant and death. The incidence of severe liver damage is approximately 1 in every 250,000 to 300,000 [[Incidence (epidemiology)|patient-years]].<ref name=WHOPN2004/><ref name=USlabel2005/>

 


 
Common and mild [[side effect]]s of nefazodone reported in [[clinical trial]]s more often than [[placebo]] include [[dry mouth]] (25%), sleepiness (25%), nausea (22%), dizziness (17%), blurred vision (16%), [[weakness]] (11%), lightheadedness (10%), confusion (7%), and [[orthostatic hypotension]] (5%). Rare and serious adverse reactions may include allergic reactions, fainting, [[priapism|painful/prolonged erection]], and [[jaundice]].<ref name=USlabel2005/>

 


 
Nefazodone is not especially associated with increased appetite and weight gain.<ref name="pmid11379839">{{cite journal |vauthors=Sussman N, Ginsberg DL, Bikoff J | title = Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials | journal = The Journal of Clinical Psychiatry | volume = 62 | issue = 4 | pages = 256â€“60 |date=April 2001 | pmid = 11379839 | doi = 10.4088/JCP.v62n0407| url = }}</ref>

 

